| Unique ID issued by UMIN | UMIN000043045 |
|---|---|
| Receipt number | R000049142 |
| Scientific Title | A prospective cohort study of combination of Clostridium butyricum therapy and immune therapy for thoracic malignancies |
| Date of disclosure of the study information | 2021/01/20 |
| Last modified on | 2026/01/22 10:04:34 |
A prospective cohort study of combination of Clostridium butyricum therapy and immune therapy for thoracic malignancies
A prospective cohort study of combination of Clostridium butyricum therapy and immune therapy for thoracic malignancies
A prospective cohort study of combination of Clostridium butyricum therapy and immune therapy for thoracic malignancies
A prospective cohort study of combination of Clostridium butyricum therapy and immune therapy for thoracic malignancies
| Japan |
Thoracic malingancies
| Pneumology | Hematology and clinical oncology |
Malignancy
NO
This prospective observational study aims to investigate changes in fecal microbiota before and after immune therapy in patients with thoracic malignancies, and to assess the impact of concomitant use of Clostridium butyricum.
Others
Changes in fecal microflora pre and post treatment with immune therapy
Exploratory
Not applicable
Changes in fecal microflora pre and post treatment with immune therapy
The following survival and safety analyses
Progression free survival(PFS)
1 year survival rate
Overall survival
Objective response rate
Duration of response
Safety (irAEs, diarrhea, etc.)
Survival analysis of cases with antibiotic drugs
Survival analysis of cases with proton pump inhibitor
Analysis of the relationship with the results of food intake questionnaire
Observational
| 20 | years-old | <= |
| Not applicable |
Male and Female
1. Histologically or cytologically confirmed thoracic malignancies
2. The patient is scheduled to receive an immune therapy.
3. History of chemotherapy is not required.
4. Presence of measurable lesions is not required.
5. ECOG PS is not required.
6. Patients must be at least 20 years of age.
7. Expression of PD-L1 is not required.
8. Consent has been obtained in writing.
None
400
| 1st name | Yusuke |
| Middle name | |
| Last name | Tomita |
Kumamoto University Hospital
Department of Respiratory Medicine
860-8556
1-1-1,Honjo,Chuo-ku,Kumamoto, Japan
096-373-5012
y-tomita@kumadai.jp
| 1st name | Tokunaga |
| Middle name | |
| Last name | Ryuki |
Kumamoto University Hospital
Department of Respiratory Medicine
860-8556
1-1-1,Honjo,Chuo-ku,Kumamoto, Japan
096-373-5012
nyamo317@hotmail.co.jp
Kumamoto University Hospital
None
Self funding
None
None
Kumamoto University Hospital
1-1-1,Honjo,Chuo-ku,Kumamoto, Japan
096-373-5012
ski-shien@jimu.kumamoto-u.ac.jp
NO
熊本大学病院(熊本県)
| 2021 | Year | 01 | Month | 20 | Day |
Unpublished
Enrolling by invitation
| 2020 | Year | 12 | Month | 17 | Day |
| 2021 | Year | 03 | Month | 02 | Day |
| 2021 | Year | 04 | Month | 01 | Day |
| 2029 | Year | 09 | Month | 30 | Day |
Changes in fecal flora pre and post treatment with immune therapy, and the following survival and safety analyses will be performed with and without concomitant use of Clostridium butyricum.
Progression-free survival (PFS)
1-year survival rate
Overall survival (OS)
Response rate (ORR)
Duration of response (DOR)
Safety (immune-related adverse events, diarrhea, etc.)
Survival analysis in patients using antibiotic therapy
Survival analysis in patients using proton pump inhibitors
Analysis of relationship with food intake questionnaire results
| 2021 | Year | 01 | Month | 18 | Day |
| 2026 | Year | 01 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049142